Advancing Drug Safety Through Prospective Pharmacovigilance

Area of Science:

• Pharmacovigilance and Regulatory Science
• Drug Development and Real-World Evidence
• Health Technology Assessment

Background:

• Current debates focus on the evidence required for early treatment introduction, balancing smaller adaptive datasets with post-approval monitoring.
• Patient-focused drug development and real-world evidence are driving changes in clinical trial designs and endpoint modifications.
• The global regulatory landscape is rapidly evolving, necessitating enhanced pharmacovigilance capabilities to ensure safe and effective patient care.

Discussion:

• The transition to adaptive regulatory frameworks and real-world data integration requires robust pharmacovigilance systems.
• Variable national capacities for regulatory oversight and pharmacovigilance contribute to significant healthcare inequalities worldwide.
• Developing validated predictive pharmacovigilance tools is crucial for understanding real-world drug risk-effectiveness.

Key Insights:

• Predictive pharmacovigilance aids regulatory authorities in assessing the gap between predicted and actual drug performance.
• It leverages electronic health information to enhance health outcomes, care quality, and patient safety.
• Recognizing the value of imperfect real-world reporting, including absence of reporting, as a postmarketing signal is vital.

Outlook:

• Predictive pharmacovigilance offers particular utility for smaller regulatory agencies with limited resources.
• It supports a proactive approach to drug safety by anticipating potential issues before they escalate.
• The integration of predictive and traditional pharmacovigilance methodologies will refine risk-benefit assessments for new medicines.